Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 10/20 | 0.73 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.69 |
| ▸ | HSP90AA1 | P07900 | 10/20 | 0.69 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1963741 | 0.94 | ERBB2 (0.75) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL5515306 | 0.85 | ERBB2 (0.73) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL27774755 | 0.85 | ERBB2 (0.72) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL1966093 | 0.85 | ERBB2 (0.84) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL3125860 | 0.85 | ERBB2 (0.80) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL1966387 | 0.85 | ERBB2 (0.82) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL3117333 | 0.84 | ERBB2 (0.68) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL1964645 | 0.84 | ERBB2 (1.00) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL3126721 | 0.84 | ERBB2 (0.67) | ERBB2HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL3116846 | 0.83 | ERBB2 (0.78) | ERBB2HSP90AB1HSP90AA1HSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | claimed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | claimed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | ERBB2 1609/4885HSP90AB1 1/4885HSP90AA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.